Payment overview · 2025
General Payments
$325.61
15 reported records · 10 companies
Healthcare provider profile · identity verified
Stephen Barnes Perez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1003953852
Verified facts
What the public records show
CMS Open Payments records show Stephen Barnes Perez, M.D. received $325.61 in general payments during 2025 across 15 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Nexletol, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.44 | 21.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.63 | 21.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.48 | 11.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.56 | 8.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.31 | 7.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.06 | 7.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $22.73 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.36 | 5.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.27 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.77 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.61 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 293 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 57 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
293 | 75 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 819 | 241 |
| Diclofenac Sodium | Diclofenac Sodium | 674 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 604 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 147 |
| Metformin Hcl | Metformin Hcl | 454 | 132 |
| Ezetimibe | Ezetimibe | 408 | 119 |
| Omeprazole | Omeprazole | 400 | 110 |
| Losartan Potassium | Losartan Potassium | 345 | 93 |
| Lisinopril | Lisinopril | 342 | 95 |
| Jardiance | Empagliflozin | 293 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 79 |
| Gabapentin | Gabapentin | 279 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 76 |
| Famotidine | Famotidine | 257 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 72 |
| Baclofen | Baclofen | 219 | 71 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 212 | 77 |
| Ibuprofen | Ibuprofen | 208 | 69 |
| Naproxen | Naproxen | 203 | 43 |
| Meclizine Hcl | Meclizine Hcl | 175 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 51 |
| Januvia | Sitagliptin Phosphate | 154 | 47 |
| Ammonium Lactate | Ammonium Lactate | 151 | 37 |
| Single Use Swab | Alcohol Antiseptic Pads | 138 | 39 |
| Trazodone Hcl | Trazodone Hcl | 133 | 43 |
| Meloxicam | Meloxicam | 132 | 36 |
| Vascepa | Icosapent Ethyl | 129 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 124 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 29 |
| Alendronate Sodium | Alendronate Sodium | 107 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 89 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 28 |
| Chlorthalidone | Chlorthalidone | 86 | 25 |
| Nifedipine Er | Nifedipine | 86 | 18 |
| Montelukast Sodium | Montelukast Sodium | 74 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 22 |
| Lidocaine | Lidocaine | 68 | 14 |
| Ozempic | Semaglutide | 67 | 17 |
| Clotrimazole | Clotrimazole | 65 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 18 |
| Nexletol | Bempedoic Acid | 62 | 18 |
| Kerendia | Finerenone | 57 | 19 |
| Finasteride | Finasteride | 56 | 20 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 54 | 12 |
| Hydrocortisone | Hydrocortisone | 52 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 24 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 46 | 23 |
| Valsartan | Valsartan | 46 | 12 |
| Carvedilol | Carvedilol | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 35 | 16 |
| Procto-Med Hc | Hydrocortisone | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 29 | suppressed |
| Ibu | Ibuprofen | 28 | 12 |
| Glipizide | Glipizide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | 11 |
| Proctozone-Hc | Hydrocortisone | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.61 · 15 records | Bayer Healthcare Pharmaceuticals Inc. | FARXIGA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, Xhance, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error